BioWorld

Sep. 3, 2004

Achillion Gets $10.4M As Part Of Series D, Names New CEO

Achillion Pharmaceuticals Inc. on Thursday closed a $10.4 million financing and announced the appointment of Michael Kishbauch as president and CEO. (BioWorld Today) Read More

Orion Tobacco Genome Work Extended To Net More Money

Spinout DCV Tech Focusing On Dendritic-Cell Cancer Vaccines

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for Jan 15, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 15, 2026.

SERPINB1 as potential biomarker for spinocerebellar ataxia type 2

BioWorld Science

Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...

Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

BioWorld

With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...

Businesswoman pressing dollar sign on touchscreen

JPM 2026: Year kicks off with biopharma Q4 revenue and guidance

BioWorld

It was a battle of the companies with drugs for transthyretin-mediated amyloidosis on the first day of the J.P. Morgan 2026 Healthcare Conference with Alnylam...